How to buy Benitec Biopharma stock

Benitec Biopharma Inc is a biotechnology business based in the US. Benitec Biopharma shares (BNTC) are listed on the NASDAQ and all prices are listed in US Dollars. Benitec Biopharma employs 14 staff and has a trailing 12-month revenue of around 0.00.

Benitec Biopharma share price

Use our graph to track the performance of BNTC stocks over time.

Benitec Biopharma shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$2.30 - $10.32
50-day moving average	$4.69
200-day moving average	$3.67
Wall St. target price	$14.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.82

Buy Benitec Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Benitec Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Benitec Biopharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Benitec Biopharma financials

Revenue TTM	$48,000
Gross profit TTM	$287,000
Return on assets TTM	-42.95%
Return on equity TTM	-73.62%
Profit margin	0%
Book value	$3.22
Market capitalisation	$20.3 million

TTM: trailing 12 months

Shorting Benitec Biopharma shares

There are currently 280,547 Benitec Biopharma shares held short by investors – that's known as Benitec Biopharma's "short interest". This figure is 20.9% up from 232,019 last month.

There are a few different ways that this level of interest in shorting Benitec Biopharma shares can be evaluated.

Benitec Biopharma's "short interest ratio" (SIR)

Benitec Biopharma's "short interest ratio" (SIR) is the quantity of Benitec Biopharma shares currently shorted divided by the average quantity of Benitec Biopharma shares traded daily (recently around 7.0 million). Benitec Biopharma's SIR currently stands at 0.04. In other words for every 100,000 Benitec Biopharma shares traded daily on the market, roughly 40 shares are currently held short.

However Benitec Biopharma's short interest can also be evaluated against the total number of Benitec Biopharma shares, or, against the total number of tradable Benitec Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Benitec Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Benitec Biopharma shares in existence, roughly 60 shares are currently held short) or 0.0584% of the tradable shares (for every 100,000 tradable Benitec Biopharma shares, roughly 58 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Benitec Biopharma.

Find out more about how you can short Benitec Biopharma stock.

Benitec Biopharma share dividends

We're not expecting Benitec Biopharma to pay a dividend over the next 12 months.

Have Benitec Biopharma's shares ever split?

Benitec Biopharma's shares were split on a 2:3 basis on 14 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Benitec Biopharma shares – just the quantity. However, indirectly, the new 50% higher share price could have impacted the market appetite for Benitec Biopharma shares which in turn could have impacted Benitec Biopharma's share price.

Benitec Biopharma share price volatility

Over the last 12 months, Benitec Biopharma's shares have ranged in value from as little as $2.3 up to $10.3213. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Benitec Biopharma's is 1.8163. This would suggest that Benitec Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Benitec Biopharma overview

Benitec Biopharma Inc. , a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California. .

Frequently asked questions

• What percentage of Benitec Biopharma is owned by insiders or institutions?

  Currently 27.038% of Benitec Biopharma shares are held by insiders and 13.458% by institutions.

• How many people work for Benitec Biopharma?

  Latest data suggests 14 work at Benitec Biopharma.

• When does the fiscal year end for Benitec Biopharma?

  Benitec Biopharma's fiscal year ends in June.

• Where is Benitec Biopharma based?

  Benitec Biopharma's address is: 3940 Trust Way, Hayward, CA, United States, 94545

• What is Benitec Biopharma's ISIN number?

  Benitec Biopharma's international securities identification number is: US08205P1003

• What is Benitec Biopharma's CUSIP number?

  Benitec Biopharma's Committee on Uniform Securities Identification Procedures number is: 082053208